Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $18.58 Consensus Price Target from Brokerages

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $17.4615.

Several equities analysts have commented on ATEC shares. Piper Sandler restated an “overweight” rating and issued a $14.00 price target (down from $25.00) on shares of Alphatec in a research note on Wednesday, May 6th. Needham & Company LLC lowered their target price on shares of Alphatec from $25.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Barclays decreased their price objective on Alphatec from $27.00 to $24.00 and set an “overweight” rating for the company in a report on Thursday, May 7th. Stifel Nicolaus dropped their price target on Alphatec from $16.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday. Finally, JPMorgan Chase & Co. cut their price objective on shares of Alphatec from $24.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th.

Insider Activity at Alphatec

In other news, Director Karen K. Mcginnis sold 6,050 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $8.01, for a total transaction of $48,460.50. Following the sale, the director owned 94,671 shares of the company’s stock, valued at $758,314.71. The trade was a 6.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 13.48% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alphatec

A number of large investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd purchased a new position in shares of Alphatec during the 3rd quarter worth approximately $34,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Alphatec by 157.1% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,571 shares of the medical technology company’s stock worth $54,000 after acquiring an additional 1,571 shares during the period. Summit Securities Group LLC acquired a new position in shares of Alphatec in the 1st quarter valued at $29,000. Osterweis Capital Management Inc. purchased a new stake in shares of Alphatec during the 2nd quarter valued at $37,000. Finally, FNY Investment Advisers LLC purchased a new stake in Alphatec during the third quarter valued at about $74,000. 66.35% of the stock is owned by institutional investors and hedge funds.

Alphatec Price Performance

ATEC opened at $9.21 on Thursday. The stock’s 50-day moving average price is $8.36 and its 200 day moving average price is $12.35. The company has a current ratio of 1.90, a quick ratio of 1.12 and a debt-to-equity ratio of 40.35. Alphatec has a 12-month low of $6.82 and a 12-month high of $23.29. The firm has a market cap of $1.42 billion, a price-to-earnings ratio of -11.23 and a beta of 0.85.

About Alphatec

Alphatec Holdings, Inc (NASDAQ: ATEC) is a medical technology company focused on the design, development and commercialization of products for the surgical correction of degenerative spinal conditions. The company’s portfolio centers on interbody implants, biologics, fixation devices and surgical planning tools intended to improve patient outcomes in spinal fusion procedures. Alphatec’s flagship offerings include customizable interbody cages, bone graft materials and specialized instrumentation designed for minimally invasive and open spinal surgeries.

Founded as Alphatec Spine in 1985 and rebranded as Alphatec Holdings in 2018, the company has grown from a single-product organization into a multi-platform innovator in the spine market.